Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $28 | $62 | $27 | $32 |
| Short-Term Investments | $183 | $172 | $165 | $166 |
| Receivables | $5 | $4 | $2 | $2 |
| Inventory | $0 | $0 | $8 | $6 |
| Other Curr. Assets | $5 | $5 | $1 | $2 |
| Total Curr. Assets | $221 | $243 | $203 | $208 |
| Property Plant & Equip (Net) | $24 | $24 | $25 | $23 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $73 | $15 | $16 | $28 |
| Tax Assets | $4 | $4 | $7 | $6 |
| Other NC Assets | $1 | $1 | $2 | $3 |
| Total NC Assets | $103 | $42 | $50 | $60 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $324 | $286 | $253 | $268 |
| Liabilities | – | – | – | – |
| Payables | $3 | $2 | $1 | $2 |
| Short-Term Debt | $4 | $4 | $6 | $5 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $1 | $1 |
| Other Curr. Liab. | $14 | $10 | $10 | $9 |
| Total Curr. Liab. | $21 | $16 | $17 | $17 |
| LT Debt | $50 | $35 | $46 | $45 |
| Deferred Rev, NC | $1 | $1 | $1 | $3 |
| Deferred Tax Liab, NC | $11 | $11 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $61 | $47 | $47 | $48 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $11 | $11 | $18 | $16 |
| Total Liabilities | $82 | $63 | $65 | $65 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$410 | -$377 | -$349 | -$331 |
| AOCI | -$1 | $0 | -$1 | -$0 |
| Other Equity | $653 | $599 | $538 | $535 |
| Total Equity | $242 | $222 | $188 | $203 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $324 | $286 | $253 | $268 |
| Net Debt | $26 | -$23 | $26 | $19 |